Heme from failing mitochondria locks T cells into permanent exhaustion

For all the progress in cancer immunotherapy, one stubborn problem keeps undermining it: the immune cells sent to kill tumors eventually stop fighting. They do not die. They do not leave. They just quit. Immunologists call this T cell exhaustion, and for years, the assumption was that it stemmed from chronic antigen exposure wearing cells down over time - the immune equivalent of burnout from overwork. But a new study from the University of Lausanne reveals a far more specific mechanism, one that reframes exhaustion as the output of a structured metabolic signaling circuit rather than simple fatigue.

A metabolic distress signal, not wear and tear

The research team, led by first author Y. Xu under the supervision of Professor Ping-Chih Ho at the Faculty of Biology and Medicine, traced the exhaustion process to a precise molecular cascade that begins in damaged mitochondria and ends in the nucleus. The chain reaction goes like this:

When mitochondria in CD8+ T cells lose their membrane potential - a well-documented feature of tumor-infiltrating lymphocytes - the cell responds by ramping up its proteasome activity. These protein-shredding molecular complexes start dismantling mitochondrial hemoproteins, releasing free regulatory heme - an iron-containing molecule normally locked safely inside functional proteins. Previous work had stopped at observing the mitochondrial damage. This study followed the consequences downstream to their logical and damaging conclusion.

That free heme does not just float around as metabolic debris. It gets actively transported to the nucleus by a chaperone protein called PGRMC2 (progesterone receptor membrane component 2). Once there, it binds to and destabilizes Bach2, a transcription factor that normally keeps the gene Blimp1 in check. Bach2 acts as a molecular brake on terminal differentiation - it maintains the T cell in a stem-like state capable of self-renewal and sustained immune response. Remove that brake, and Blimp1 - a master regulator of terminal exhaustion programs - takes over without opposition.

The T cell's fate is sealed at that point. It loses its stem-like renewal capacity and enters a dysfunctional state from which it cannot recover through any normal biological process. The exhaustion is not a temporary condition but a stable transcriptional reprogramming event.

Two proteins that enable the chain reaction

The pathway depends on at least two additional molecular players the team identified beyond the proteasome itself. CBLB, an E3 ubiquitin ligase, drives the ubiquitination of mitochondrial proteins, tagging them for proteasomal degradation and effectively feeding the heme-release machine. PGRMC2 then escorts the liberated heme from the cytoplasm into the nucleus, ensuring the signal reaches its target.

Without either of these components, the signal chain breaks at different points. This specificity matters enormously. It means the pathway is not some generalized stress response that would be difficult to target without widespread side effects but rather a structured signaling circuit with identifiable, druggable nodes along its length.

Bortezomib rescues T cells at the manufacturing stage

The most immediate practical implication involves CAR-T cell therapy, where T cell exhaustion during the manufacturing process is a recognized problem that limits treatment durability. The team demonstrated that treating T cells with transient, low-dose bortezomib - an FDA-approved proteasome inhibitor already in widespread clinical use for multiple myeloma - during the ex vivo manufacturing phase dampened the proteasome-driven heme release that initiates the exhaustion cascade.

The results went beyond simply delaying exhaustion. Bortezomib treatment promoted durable epigenetic reprogramming toward a memory-like state - the kind of T cell phenotype that persists long-term in the body and retains the capacity to mount repeated, effective responses against recurring tumor cells. Memory T cells are the gold standard for long-lived immunity, and coaxing manufactured CAR-T cells toward this phenotype has been a persistent challenge in the field.

Clinical data from patients with B-cell acute lymphoblastic leukemia (B-ALL) reinforced the finding's relevance to human disease. CAR-T cells exhibiting high proteasome activity in patient samples correlated with poorer therapeutic outcomes. The molecular observations from the bench aligned with what clinicians were seeing at the bedside, tightening the argument that this pathway operates in actual patients, not just in controlled laboratory conditions.

A different way to think about immune failure

The conventional view treats T cell exhaustion as a consequence of chronic stimulation - too much antigen exposure for too long drives cells into a worn-out state. This study reframes it as the output of a triggered metabolic signaling circuit that converts mitochondrial stress into a permanent transcriptional decision. The distinction matters because it changes where therapeutic intervention should be directed.

If exhaustion is simply about overstimulation, the logical therapeutic response is to reduce antigen exposure, provide rest periods, or block inhibitory receptor signaling through checkpoint inhibitors. If it is driven by a specific proteasome-heme-transcription factor axis, you can target the mechanism directly at any of several molecular nodes without needing to alter the fundamental conditions of antigen exposure.

The finding also bridges two previously separate observations in the immunology literature. Mitochondrial dysfunction in exhausted T cells was well documented but mechanistically unexplained - an observation without a clear causal story. The Bach2-Blimp1 axis was known to regulate T cell fate decisions. This study provides the molecular connection between them: regulatory heme acting as the signaling intermediary that translates metabolic damage into transcriptional commitment.

What this does not yet prove

Several important caveats apply to the work. The bortezomib intervention was tested during ex vivo CAR-T manufacturing, not as an in vivo systemic treatment. Whether administering proteasome inhibitors directly to patients could rescue exhausted T cells already residing inside tumors is an entirely separate and more complicated question. Bortezomib has broad effects across multiple cell types, and its systemic use for T cell reinvigoration would need to contend with off-target impacts on other immune and non-immune cells.

The work relies substantially on mouse models and in vitro systems for its mechanistic claims. While the B-ALL patient data provides clinical correlation, correlation is not causation. The step from correlative clinical data to a confirmed therapeutic strategy requires prospective clinical testing - randomized trials comparing CAR-T cells manufactured with and without proteasome inhibition.

It remains unclear how this pathway interacts with checkpoint blockade therapies like anti-PD-1 and anti-CTLA-4, which operate through different mechanisms of T cell reinvigoration. Whether the heme-Bach2 axis represents an entirely independent exhaustion driver or intersects with checkpoint signaling pathways at some point remains to be determined. Understanding this interaction will be important for designing combination therapeutic strategies.

Near-term and longer-term applications

The most near-term application is straightforward: incorporating transient proteasome inhibition into existing CAR-T cell manufacturing protocols. Bortezomib is inexpensive, well-characterized in terms of pharmacology and safety profile, and already clinically approved for other indications. This substantially lowers the regulatory and practical barriers to testing this approach in formal clinical trials. If it works, it could improve the durability and effectiveness of CAR-T responses without requiring any novel drug development.

Longer term, the identification of PGRMC2 as the nuclear heme transport chaperone opens a second, potentially more specific intervention point. Blocking PGRMC2-mediated nuclear heme translocation could theoretically preserve Bach2 and prevent the exhaustion program from activating, even in cells with severely damaged mitochondria. But PGRMC2 inhibitors are not currently in clinical development for this indication, and developing them would require a longer timeline.

The study was conducted by researchers at the University of Lausanne in collaboration with institutions across Switzerland, China, Taiwan, the United Kingdom, and the United States. Funding came from the Swiss National Science Foundation, the Swiss Cancer Foundation, the Cancer Research Institute, the Helmut Horten Stiftung, the Melanoma Research Alliance, and multiple international funding bodies.